EU/3/09/706

Table of contents

About

On 28 January 2010, orphan designation (EU/3/09/706) was granted by the European Commission to Medesis Pharma, France, for lithium citrate tetrahydrate (in reverse-micelle formulation) for the treatment of Huntington's disease.

Key facts

Active substance
Lithium citrate tetrahydrate (in reverse-micelle formulation)
Disease / condition
Treatment of Huntington’s disease
Date of first decision
28/01/2010
Outcome
Positive
EU designation number
EU/3/09/706

Sponsor's contact details

 L'Orée des Mas
Avenue du Golf
34670 Baillargues
France
Telephone: +33 4 67 03 03 99
Telefax: +33 4 67 72 26 21
E-mail: jc-maurel@medesispharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating